ArticleApplied and environmental microbiology2013
Comparative transcription profiling and in-depth characterization of plasmid-based and plasmid-free Escherichia coli expression systems under production conditions.
Article in Applied and environmental microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 85 citations in OpenAlex.
- Whole-cell surface-display system in attenuated Salmonella Enteritidis for slide microagglutination-based antibody detection.Microbial cell factories · 2026Article
- Leaky recombinant expression reveals design constraints of bicistronic synthetic operons in Escherichia coli.Scientific reports · 2026Article
- Catalytically active inclusion bodies of Bacillus clausii laccase protein recombinantly produced in E. coli for dye decolorization.Microbial cell factories · 2026Article
- Biosynthesis of poly(3-hydroxybutyrate-Biodesign research · 2025Article
- Residue-Specific Incorporation of Noncanonical Amino Acids in Auxotrophic Hosts:Chemical reviews · 2025Review
- Exploring auxotrophy and engineering vitamin BApplied and environmental microbiology · 2024Article
- Plasmid-free production of the plant lignan pinoresinol in growing Escherichia coli cells.Microbial cell factories · 2024Article
- Application of plasmid stabilization systems for heterologous protein expression in Escherichia coli.Molecular biology reports · 2024Article
- Feasibility of engineeredBioengineering & translational medicine · 2024Article
- Proteomics and metabolic burden analysis to understand the impact of recombinant protein production in E. coli.Scientific reports · 2024Article
- Transcriptional biomarker discovery toward building a load stress reporting system for engineered Escherichia coli strains.Biotechnology and bioengineering · 2024Article
- Developing a dynamic equilibrium system in Escherichia coli to improve the production of recombinant proteins.Applied microbiology and biotechnology · 2022Article
- Process intensification at the expression system level for the production of 1-phosphate aldolase in antibiotic-free E. coli fed-batch cultures.Journal of industrial microbiology & biotechnology · 2022Article
- Metabolic engineering of Clostridium ljungdahlii for the production of hexanol and butanol from COMicrobial cell factories · 2022Article
- Interaction of Periplasmic Fab Production and Intracellular Redox Balance inACS synthetic biology · 2022Article
- The Effect of Recombinant Protein Production inMicroorganisms · 2022Review
- Xer recombination for the automatic deletion of selectable marker genes from plasmids in enteric bacteria.Synthetic biology (Oxford, England) · 2022Article
- Methods for the Development of Recombinant Microorganisms for the Production of Natural Products.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Whole cell-based catalyst for enzymatic production of the osmolyte 2-O-α-glucosylglycerol.Microbial cell factories · 2021Article
- Optimized gene expression from bacterial chromosome by high-throughput integration and screening.Science advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmid-based Escherichia coli BL21(DE3) expression systems are extensively used for the production of recombinant proteins. However, the combination of a high gene dosage with strong promoters exerts extremely stressful conditions on producing cells, resulting in a multitude of protective reactions and malfunctions in the host cell with a strong impact on yield and quality of the product. Here, we provide in-depth characterization of plasmid-based perturbations in recombinant protein production. A plasmid-free T7 system with a single copy of the gene of interest (GOI) integrated into the genome was used as a reference. Transcriptomics in combination with a variety of process analytics were used to characterize and compare a plasmid-free T7-based expression system to a conventional pET-plasmid-based expression system, with both expressing human superoxide dismutase in fed-batch cultivations. The plasmid-free system showed a moderate stress response on the transcriptional level, with only minor effects on cell growth. In contrast to this finding, comprehensive changes on the transcriptome level were observed in the plasmid-based expression system and cell growth was heavily impaired by recombinant gene expression. Additionally, we found that the T7 terminator is not a sufficient termination signal. Overall, this work reveals that the major metabolic burden in plasmid-based systems is caused at the level of transcription as a result of overtranscription of the multicopy product gene and transcriptional read-through of T7 RNA polymerase. We therefore conclude that the presence of high levels of extrinsic mRNAs, competing for the limited number of ribosomes, leads to the significantly reduced translation of intrinsic mRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.